Evidence map›Paper›PMID 25344369›Full record

ReviewCardiovascular research2014

ESC working group cellular biology of the heart: position paper: improving the preclinical assessment of novel cardioprotective therapies.

Sandrine Lecour, Hans E Bøtker, Gianluigi Condorelli, Sean M Davidson, David Garcia-Dorado, Felix B Engel, Peter Ferdinandy, Gerd Heusch, Rosalinda Madonna, Michel Ovize and 6 more

Abstract readReviewConsensus Statement
PubMed Full text at PMC Publisher
In one paragraph

Review in Cardiovascular research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 81 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
81citing papers in PubMed, 7 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

81 citing papers in PubMed, 7 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Guideline
  7. Pooled it
  8. Trial
  9. Trial
  10. [Research progress on the metabolic regulatory mechanisms of coronary collateral circulation].Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2026
    Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Direct cardiac reprogramming: A new technology for cardiac repair.Journal of molecular and cellular cardiology · 2023
    Review
  18. Review
  19. Article
  20. Article

21 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors.

Sandrine LecourHatter Institute for Cardiovascular Research in Africa and MRC Inter-University Cape Heart Group, University of Cape Town, Cape Town, South Africa.
Hans E BøtkerDepartment of Cardiology, Aarhus University Hospital Skejby, Aarhus N, Denmark.
Gianluigi CondorelliHumanitas Clinical and Research Institute, National Research Council of Italy, Rozzano, Italy.
Sean M DavidsonThe Hatter Cardiovascular Institute, University College London, 67 Chenies Mews.
David Garcia-DoradoDepartment of Cardiology, Vall d'Hebron University Hospital and Research Institute, Universitat Autónoma de Barcelona, Barcelona, Spain.
Felix B EngelExperimental Renal and Cardiovascular Research, Department of Nephropathology, Institute of Pathology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany.
Peter FerdinandyDepartment of Pharmacology and Pharmacotherapy, Semmelweis University, Budapest, Hungary Pharmahungary Group, Szeged, Hungary.
Gerd HeuschInstitut für Pathophysiologie, West German Heart and Vascular Centre, Universitätsklinikum Essen, Essen, Germany.
Rosalinda MadonnaInstitute of Cardiology and Center of Excellence on Aging, 'G. d'Annunzio' University of Chieti, Chieti, Italy Texas Heart Institute, Houston, TX, USA Department of Internal Medicine, University of Texas Medical School, Center of Cardiovascular and Atherosclerosis Research, Houston, TX, USA.
Michel OvizeInserm U 1060 (CarMeN_Cardioprotection Team) & CIC de Lyon, Service d'Exploration Fonctionnelles Cardiovasculaires, Hospices Civils de Lyon, Université Claude Bernard Lyon1, Lyon, France.
Marisol Ruiz-MeanaDepartment of Cardiology, Vall d'Hebron University Hospital and Research Institute, Universitat Autónoma de Barcelona, Barcelona, Spain.
Rainer SchulzJustus Liebig University Giessen, Giessen, Germany.
Joost P G SluijterUniversity Medical Center Utrecht, Utrecht, the Netherlands.
Linda W Van LaakeUniversity Medical Center Utrecht and Hubrecht Institute, Utrecht, the Netherlands.
Derek M YellonThe Hatter Cardiovascular Institute, University College London, 67 Chenies Mews.
Derek J HausenloyThe Hatter Cardiovascular Institute, University College London, 67 Chenies Mews d.hausenloy@ucl.ac.uk.

Funding

British Heart Foundation RG/08/015/26411Medical Research Council MR/K002066/1
6 · The paper itself

Abstract

Ischaemic heart disease (IHD) remains the leading cause of death and disability worldwide. As a result, novel therapies are still needed to protect the heart from the detrimental effects of acute ischaemia-reperfusion injury, in order to improve clinical outcomes in IHD patients. In this regard, although a large number of novel cardioprotective therapies discovered in the research laboratory have been investigated in the clinical setting, only a few of these have been demonstrated to improve clinical outcomes. One potential reason for this lack of success may have been the failure to thoroughly assess the cardioprotective efficacy of these novel therapies in suitably designed preclinical experimental animal models. Therefore, the aim of this Position Paper by the European Society of Cardiology Working Group Cellular Biology of the Heart is to provide recommendations for improving the preclinical assessment of novel cardioprotective therapies discovered in the research laboratory, with the aim of increasing the likelihood of success in translating these new treatments into improved clinical outcomes.

Indexed as

Evaluation Studies as TopicTranslational Research, BiomedicalAnimalsDisease Models, AnimalMyocardial IschemiaAnimal modelsCardioprotectionIschaemiaMyocardial infarctionReperfusion

Identifiers

PMID25344369
PMCPMC4242141

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.